DOCSLIB.ORG

Treatment Strategies for Allergy and Asthma

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Treatment Strategies for Allergy and Asthma REVIEWS Treatment strategies for allergy and asthma Stephen T. Holgate* and Riccardo Polosa‡ Abstract | Allergic diseases have reached epidemic proportions worldwide. An understanding of the cellular and soluble mediators that are involved in allergic inflammatory responses not only helps in understanding the mechanisms of current treatments, but is also important for the identification of new targets that are amenable to both small-molecule and biological interventions. There is now considerable optimism with regards to tackling the allergy epidemic in light of improvements in systemic and mucosal allergen-specific immunotherapy, the identification of key cytokines and their receptors that drive T-helper-2-cell polarization, a clearer understanding of the pathways of leukocyte recruitment and the signalling pathways that are involved in cell activation and mediator secretion, and new approaches to vaccine development. T helper 2 cells Allergic diseases are those that are mediated by the mediators involved and the innate and adaptive immune (T 2 cells). A T-helper-cell T helper 2 cell H expansion of the (TH2-cell) subset of responses that regulate its expression. Progress has also subset that has an important T cells, together with isotype switching of B cells to gen- occurred in understanding the structural and intrinsic role in humoral immunity and erate IgE antibodies specific for common environmental biology of environmental agents that determine their in allergic responses. T 2 cells H 1 produce cytokines that allergens . Although almost half of the urban population allergenicity, and the role of other environmental factors, regulate IgE synthesis (IL‑4), worldwide is atopic (genetically predisposed to produce such as pollutants and microorganisms, in augmenting eosinophil proliferation (IL‑5), IgE antibodies in serum) and most allergy sufferers are or inhibiting allergen sensitization5. As most allergic mast-cell proliferation (IL‑9) atopic, it is possible to develop allergies in the absence disorders express themselves clinically at epidermal or and airway hyper- of atopy — common examples of this are wasp and bee mucosal surfaces, a breakdown of the physical barrier that responsiveness (IL‑13). A TH2- cell pattern of cytokine allergies. Allergic reactions are symptomatic responses is normally provided by these surfaces and altered innate expression is observed in to a normally innocuous environmental antigen. Allergic immunity is also recognized to be of great importance allergic inflammation and in diseases are highly patient specific and include asthma, in allergic reactions. The study of interactions between parasitic infections, conditions rhinoconjunctivitis, sinusitis, food allergy, atopic derma- many susceptibility genes and the environment is reveal- that are both associated with IgE production and titis, angioedema and urticaria, anaphylaxis, and insect ing new pathophysiological mechanisms and creating eosinophilia. and drug allergy, all of which can occur either alone or unique opportunities for the prevention and treatment in combination. Allergic diseases have reached epidemic of allergy. proportions worldwide and their incidence is continu- The time has arrived to take a fresh look at the new ing to increase in association with the Western lifestyle, treatment strategies that are now appearing on the making it imperative that we continue to improve our horizon. This Review provides an overview of possible 2 *IIR Division, F Level, understanding of the mechanisms of allergic disease . innovative therapeutics, focusing on some exciting new South Block, Southampton Allergies can affect all age groups and can appear at any immunological and molecular targets and on vaccine General Hospital, time, but it is the marked increase of allergies in children approaches for allergy and asthma. Southampton, SO16 6YD, UK. and young adults that is of particular concern3. It is prob- ‡ Dipartimento di Medicina The allergic cascade Interna e Specialistica, able that environmental exposure to potential allergens University of Catania, early in life or during pregnancy has a pivotal role in the The allergic inflammatory response is characterized Via Passo Gravina, development of allergy and its expression in different by selection of the TH2-cell pathway, which is initiated 187, 95,125 Catania, Italy. organs (BOX 1). by the uptake of allergens by professional antigen- Correspondence to S.T.H. Since the first description of ‘reagin’ in 1922 and its presenting cells (APCs) that present selected peptides e-mail: [email protected] (REF. 4) doi:10.1038/nri2262 characterization as IgE in 1966 , considerable on MHC class II molecules to naive T cells, thereby Published online advances have been made in understanding the immu- directing them in favour of a TH2-cell phenotype in 15 February 2008 nological pathways that lead to allergy, the chemical which the transcription factor GATA3 (GATA-binding 218 | march 2008 | VOLUme 8 www.nature.com/reviews/immunol © 2008 Nature Publishing Group FOCUs ON ALLerGY AND REVIEWSAsTHMA Box 1 | Early-life influences in the development of allergy and asthma strongly implicate TReg cells in the suppression of aller- gic responses14, and there is emerging evidence that Environmental exposure to allergens that occurs early in life or during pregnancy is T cells also control T 2-cell responses in humans thought to initiate the allergic response to increase T helper 2 (T 2)-cell and decrease Reg H H through the inhibitory cytokines IL‑10 and transform- T 1-cell and regulatory T-cell subpopulations. H ing growth factor-β (TGFβ), with atopy resulting from Strong allergy-protective factors have been observed in farming environments. This 15 protective effect can be explained by dietary habits, lifestyle and environmental an imbalance between TH2 cells and TReg cells . Another newly identified type of CD4+ T cell exposures, and it is associated with an increased production of the TH1-cell cytokines tumour-necrosis factor and interferon-γ by cord-blood mononuclear cells. Nutritional has been named the TH17 cell on the basis of secre- factors that affect the development of allergic diseases early in life include tion of IL‑17A and IL‑17F, which are associated with breastfeeding, dietary fatty acids, antioxidants, and foods that affect the gut neutrophilic inflammation16. The transcription fac- microflora. In many industrialized societies, the decreased consumption of ω3-fatty tor RORγt (retinoic-acid-receptor-related orphan acids, which have been replaced by an increased intake of ω6-fatty acids, favours a receptor‑γt) identifies TH17 cells and is selectively T 2-cell phenotype during ontogeny and development. H activated by IL‑1β and IL‑6 (REF. 17), with IL‑23 being An imbalance between reactive oxygen and antioxidants is another factor that responsible for the proliferation of these cells. IL‑17A is contributes to the chronic inflammatory process in asthma. Deficiency in dietary overexpressed in asthmatic airways in association with antioxidants and vitamins in the Western diet, with decreased consumption of fresh 18 fruit and vegetables, correlates with changes in the prevalence of allergies and asthma. neutrophil influx and it induces production of the The mammalian gastrointestinal tract harbours a complex ecosystem consisting of neutrophil chemoattractant IL‑8 (CXCL8) by human 19 bacteria that are in homeostasis with the host immune system, and a disturbance of this airway smooth muscle cells . homeostasis might have a role in the development of allergy. Exposure to microbial Once an individual is sensitized to a particular aller- products skews the T‑cell balance towards a TH1-cell response by interacting with Toll- gen, subsequent encounters with that allergen cause like receptors (TLRs) expressed by dendritic cells. Environmental indicators of microbial crosslinking of IgE bound to the high-affinity IgE recep- exposure — such as the presence of endotoxin, muramic acid, β(1,3)-glucans and tor (FcεRI) to stimulate the release of granule-associated extracellular polysaccharides from Aspergillus spp. and Penicillium spp. — are inversely and newly generated mediators that are responsible related to the incidence of allergic diseases. Although there have been attempts to for the early allergic response (which occurs within harness protection against allergy by using microbial products such as Mycobacterium 1–30 minutes), together with the release of cytokines vaccae to stimulate a TH1-cell response, a more promising approach is the application of specific TLR ligands such as CpG oligonucleotides (which bind TLR9) and chitin and chemokines that recruit macrophages, eosinophils (which binds TLR2 and TLR4). and basophils that comprise the late response (within 6–72 hours)20. Autacoid mediators such as histamine and the cysteinyl leukotrienes (CysLTs) increase protein 3) mediates cytokine secretion6 (FIG. 1). This is in endothelial expression of P‑selectin and E‑selectin to contrast to the TH1-cell phenotype that is dominant in initiate leukocyte rolling, followed by the expression of autoimmune diseases, in which T‑bet controls cytokine intercellular adhesion molecule 1 (ICAM1) and vascu- secretion — for example, the secretion of interferon‑γ lar cell adhesion molecule 1 (VCAM1), which interact (IFNγ)7. The crucial role played by dendritic cells (DCs) with integrin receptors to arrest the leukocyte and assist acting as professional APCs in this sensitization process its passage into the perivascular space21.
Load more

Recommended publications
  • Pediatric Institute & Cleveland Clinic Children's
    Pediatric Institute & Cleveland Clinic Children’s This project would not have been possible without the commitment and expertise of a team led by Dr. Vera Hupertz, Anne Shi, and Allan Cohn. Graphic design and photography were provided by Cleveland Clinic’s Center for Medical Art and Photography. © The Cleveland Clinic Foundation 2017 9500 Euclid Avenue, Cleveland, OH 44195 clevelandclinic.org 2016 Outcomes 17-OUT-420 108373_CCFBCH_17OUT420_ACG.indd 1-3 9/7/17 1:42 PM Measuring Outcomes Promotes Quality Improvement Clinical Trials Cleveland Clinic is running more than 2200 clinical trials at any given time for conditions including breast and liver cancer, coronary artery disease, heart failure, epilepsy, Parkinson disease, chronic obstructive pulmonary disease, asthma, high blood pressure, diabetes, depression, and eating disorders. Cancer Clinical Trials is a mobile app that provides information on the more than 200 active clinical trials available to cancer patients at Cleveland Clinic. clevelandclinic.org/cancertrialapp Healthcare Executive Education Cleveland Clinic has programs to share its expertise in operating a successful major medical center. The Executive Visitors’ Program is an intensive, 3-day behind-the-scenes view of the Cleveland Clinic organization for the busy executive. The Samson Global Leadership Academy is a 2-week immersion in challenges of leadership, management, and innovation taught by Cleveland Clinic leaders, administrators, and clinicians. Curriculum includes coaching and a personalized 3-year leadership development plan. clevelandclinic.org/executiveeducation Consult QD Physician Blog A website from Cleveland Clinic for physicians and healthcare professionals. Discover the latest research insights, innovations, treatment trends, and more for all specialties. consultqd.clevelandclinic.org Social Media Cleveland Clinic uses social media to help caregivers everywhere provide better patient care.
    [Show full text]
  • Cytokine Nomenclature
    RayBiotech, Inc. The protein array pioneer company Cytokine Nomenclature Cytokine Name Official Full Name Genbank Related Names Symbol 4-1BB TNFRSF Tumor necrosis factor NP_001552 CD137, ILA, 4-1BB ligand receptor 9 receptor superfamily .2. member 9 6Ckine CCL21 6-Cysteine Chemokine NM_002989 Small-inducible cytokine A21, Beta chemokine exodus-2, Secondary lymphoid-tissue chemokine, SLC, SCYA21 ACE ACE Angiotensin-converting NP_000780 CD143, DCP, DCP1 enzyme .1. NP_690043 .1. ACE-2 ACE2 Angiotensin-converting NP_068576 ACE-related carboxypeptidase, enzyme 2 .1 Angiotensin-converting enzyme homolog ACTH ACTH Adrenocorticotropic NP_000930 POMC, Pro-opiomelanocortin, hormone .1. Corticotropin-lipotropin, NPP, NP_001030 Melanotropin gamma, Gamma- 333.1 MSH, Potential peptide, Corticotropin, Melanotropin alpha, Alpha-MSH, Corticotropin-like intermediary peptide, CLIP, Lipotropin beta, Beta-LPH, Lipotropin gamma, Gamma-LPH, Melanotropin beta, Beta-MSH, Beta-endorphin, Met-enkephalin ACTHR ACTHR Adrenocorticotropic NP_000520 Melanocortin receptor 2, MC2-R hormone receptor .1 Activin A INHBA Activin A NM_002192 Activin beta-A chain, Erythroid differentiation protein, EDF, INHBA Activin B INHBB Activin B NM_002193 Inhibin beta B chain, Activin beta-B chain Activin C INHBC Activin C NM005538 Inhibin, beta C Activin RIA ACVR1 Activin receptor type-1 NM_001105 Activin receptor type I, ACTR-I, Serine/threonine-protein kinase receptor R1, SKR1, Activin receptor-like kinase 2, ALK-2, TGF-B superfamily receptor type I, TSR-I, ACVRLK2 Activin RIB ACVR1B
    [Show full text]
  • Kate Fitzgerald
    In This Issue: 2020 Young Investigator Awardees pg. 3-9 In Memorium page pg. 14-15 New Member Mini-Bios pg. 19-21 Trials of Interferon Lambda pg. 31 Cytokines 2021 Hybrid Meetin pg. 24-27 Signals THE INTERNATIONAL CYTOKINE & INTERFERON SOCIETY + NEWSLETTER APRIL 2021 I VOLUME 9 I NO. 1 A NOTE FROM THE ICIS PRESIDENT Kate Fitzgerald Dear Colleagues, Greetings from the International Cytokine and Interferon Society! I hope you and your family are staying safe during these still challenging times. Thankfully 2020 is behind us now. We have lived through the COVID-19 pandemic, an event that will continue to impact our lives for some time and likely alter how we live in the future. Despite the obvious difficulties of this past year, I can’t help but marvel at the scientific advances that have been made. With everything from COVID-19 testing, to treatments and especially to the rapid pace of vaccine development, we are so better off today than even a few months back. The approval of remarkably effective COVID-19 vaccines now rolling out in the US, Israel, UK, Europe and across the globe, brings light at the end of the tunnel. The work of many of you has helped shape our understanding of the host response to Sars-CoV2 and the ability of this virus to limit antiviral immunity while simultaneously driving a cytokine driven hyperinflammatory response leading to deadly consequences for patients. The knowledge gained from all of your efforts has been put to good use to stem the threat of this deadly virus.
    [Show full text]
  • Increasing Prevalence of Bronchial Hyperresponsiveness in Three Selected Areas in East Germany
    Copyright #ERS Journals Ltd 2001 Eur Respir J 2001; 18: 451–458 European Respiratory Journal Printed in UK – all rights reserved ISSN 0903-1936 Increasing prevalence of bronchial hyperresponsiveness in three selected areas in East Germany C. Frye*, J. Heinrich*, M. Wjst*, H-E. Wichmann*,#, for the Bitterfeld study group Increasing prevalence of bronchial hyperresponsiveness in three selected areas in East *GSF - Forschungszentrum fu¨r Um- Germany. C. Frye, J. Heinrich, M. Wjst, H-E. Wichmann, for the Bitterfeld study welt und Gesundheit, Institut fur # Epidemiologie, Ingolstaedter Land- group. ERS Journals Ltd 2001. # ABSTRACT: The prevalence of asthma, bronchial hyperresponsiveness (BHR) and strabe 1, Neuherberg, Germany. Lehr- stuhl fu¨r Epidemiologie, Institut fu¨r allergic rhinitis in children was lower in East Germany compared to West Germany. medizinische Informationsverarbei- The reasons for this difference are still not understood. This study tested the hypothesis tung, Biometrie und Epidemiologie that prevalence of BHR increased in East German children after reunification. der Ludwig-Maximilians-Universita¨t Two consecutive cross-sectional surveys of schoolchildren aged 8–14 yrs from three Mu¨nchen, Neuherberg, Germany. communities in East Germany were carried out in 1992–1993 and 1995–1996. A subsample of 530 and 790 children with complete lung function and cold air challenge Correspondence: J. Heinrich, GSF - data was analysed. Forschungszentrum fu¨r Umwelt und The prevalence of BHR increased from 6.4% in 1992–1993 to 11.6% in 1995–1996 Gesundheit, Institut fur Epidemiologie, Ingolstaedter Landstrabe 1, D-85764 (odds ratio (OR): 2.0, 95% confidence interval (CI): 1.3–3.0, adjusted for age, sex, Neuherberg, Germany.
    [Show full text]
  • Environmental Determinants of Allergy and Asthma in Early Life
    Clinical reviews in allergy and immunology Environmental determinants of allergy and asthma in early life Allison J. Burbank, MD,* Amika K. Sood, MD,* Matthew J. Kesic, PhD, David B. Peden, MD, MS, and Michelle L. Hernandez, MD Chapel Hill, NC INFORMATION FOR CATEGORY 1 CME CREDIT Credit can now be obtained, free for a limited time, by reading the review List of Design Committee Members: Allison J. Burbank, MD, Amika articles in this issue. Please note the following instructions. K. Sood, MD, Matthew J. Kesic, PhD, David B. Peden, MD, MS, and Mi- Method of Physician Participation in Learning Process: The core ma- chelle L. Hernandez, MD terial for these activities can be read in this issue of the Journal or online at Disclosure of Significant Relationships with Relevant Commercial the JACI Web site: www.jacionline.org. The accompanying tests may only Companies/Organizations: M. L. Hernandez has received grants from be submitted online at www.jacionline.org. Fax or other copies will not be the American Academy of Allergy, Asthma & Immunology Foundation. accepted. The rest of the authors declare that they have no relevant conflicts of interest. Date of Original Release: July 2017. Credit may be obtained for these Activity Objectives: courses until June 30, 2018. 1. To describe the effect of microbial exposure and childhood infec- Ó Copyright Statement: Copyright 2017-2018. All rights reserved. tions on the risk of allergic disease. Overall Purpose/Goal: To provide excellent reviews on key aspects 2. To understand the link between indoor allergen exposure and the risk of allergic disease to those who research, treat, or manage allergic of atopy.
    [Show full text]
  • Pulmonary Delivery of Biological Drugs
    pharmaceutics Review Pulmonary Delivery of Biological Drugs Wanling Liang 1,*, Harry W. Pan 1 , Driton Vllasaliu 2 and Jenny K. W. Lam 1 1 Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, 21 Sassoon Road, Pokfulam, Hong Kong, China; [email protected] (H.W.P.); [email protected] (J.K.W.L.) 2 School of Cancer and Pharmaceutical Sciences, King’s College London, 150 Stamford Street, London SE1 9NH, UK; [email protected] * Correspondence: [email protected]; Tel.: +852-3917-9024 Received: 15 September 2020; Accepted: 20 October 2020; Published: 26 October 2020 Abstract: In the last decade, biological drugs have rapidly proliferated and have now become an important therapeutic modality. This is because of their high potency, high specificity and desirable safety profile. The majority of biological drugs are peptide- and protein-based therapeutics with poor oral bioavailability. They are normally administered by parenteral injection (with a very few exceptions). Pulmonary delivery is an attractive non-invasive alternative route of administration for local and systemic delivery of biologics with immense potential to treat various diseases, including diabetes, cystic fibrosis, respiratory viral infection and asthma, etc. The massive surface area and extensive vascularisation in the lungs enable rapid absorption and fast onset of action. Despite the benefits of pulmonary delivery, development of inhalable biological drug is a challenging task. There are various anatomical, physiological and immunological barriers that affect the therapeutic efficacy of inhaled formulations. This review assesses the characteristics of biological drugs and the barriers to pulmonary drug delivery.
    [Show full text]
  • Food Allergy in Children and Young People Diagnosis and Assessment of Food Allergy in Children and Young People in Primary Care and Community Settings
    Issue date: February 2011 Food allergy in children and young people Diagnosis and assessment of food allergy in children and young people in primary care and community settings NICE clinical guideline 116 Developed by the Centre for Clinical Practice at NICE Update information Minor changes since publication October 2018: After a surveillance review, links to other NICE guidance have been updated as needed and new links added in some recommendations. Some terminology has also been updated. These changes can be seen in the short version of the guideline at http://www.nice.org.uk/guidance/cg116 NICE clinical guidelines are recommendations about the treatment and care of people with specific diseases and conditions in the NHS in England and Wales. This guidance represents the view of NICE, which was arrived at after careful consideration of the evidence available. Healthcare professionals are expected to take it fully into account when exercising their clinical judgement. However, the guidance does not override the individual responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or guardian or carer, and informed by the summary of product characteristics of any drugs they are considering. Implementation of this guidance is the responsibility of local commissioners and/or providers. Commissioners and providers are reminded that it is their responsibility to implement the guidance, in their local context, in light of their duties to avoid unlawful discrimination and to have regard to promoting equality of opportunity. Nothing in this guidance should be interpreted in a way that would be inconsistent with compliance with those duties.
    [Show full text]
  • What You Need to Know About the New Guidelines for the Diagnosis and Management of Food Allergy in the U.S
    Allergy guidelines insert_Layout 1 9/26/11 1:36 PM Page 1 What you need to know about the new guidelines for the diagnosis and management of food allergy in the U.S. V OLUME 126, N O . 6 D ECEMBER 2010 • Tests for food-specific IgE are recom- Overview www.jacionline.org • The Guidelines, sponsored by the NIH Supplement to mended to assist in diagnosis, but should (NIAID), are based upon expert opinion THE JOURNAL OF not be relied upon as a sole means to di- Allergy ANDClinical and a comprehensive literature review. Immunology agnose food allergy. The medical history/ AAP had input on the document.1,2 exam are recommended to aid in diag- nosis. A medically monitored feeding Guidelines for the Diagnosis and Management Definitions of Food Allergy in the United States: Report of the (food challenge) is considered the most NIAID-Sponsored Expert Panel • Food allergy was defined as an adverse definitive test for food allergy. health effect arising from a specific im- • Food-specific IgE testing has numerous mune response. limitations; positive tests are not intrin- • Food allergies result in IgE-mediated sically diagnostic and reactions some- immediate reactions (e.g., anaphylaxis) OFFICIAL JOURNAL OF times occur with negative tests. These and several chronic diseases (e.g., ente- Supported by the Food Allergy Initiative issues are also reviewed in an AAP Clini - rocolitis syndromes, eosinophilic esopha - cal Report.3 Testing “food panels” with- gitis, etc), in which IgE may not play an important role. out considering history is often mis - leading. Tests selected to evaluate food allergy should be Epidemiology and Natural History based on the patient’s medical history and not comprise • Food allergy is more common in children than adults, large general panels of food allergens.
    [Show full text]
  • Novel Therapies for Eosinophilic Disorders
    Novel Therapies for Eosinophilic Disorders Bruce S. Bochner, MD KEYWORDS Eosinophil Therapies Antibodies Targets Pharmacology Biomarkers KEY POINTS A sizable unmet need exists for new, safe, selective, and effective treatments for eosinophil-associated diseases, such as hypereosinophilic syndrome, eosinophilic gastrointestinal disorders, nasal polyposis, and severe asthma. An improved panel of biomarkers to help guide diagnosis, treatment, and assessment of disease activity is also needed. An impressive array of novel therapeutic agents, including small molecules and biologics, that directly or indirectly target eosinophils and eosinophilic inflammation are undergoing controlled clinical trials, with many already showing promising results. A large list of additional eosinophil-related potential therapeutic targets remains to be pursued, including cell surface structures, soluble proteins that influence eosinophil biology, and eosinophil-derived mediators that have the potential to contribute adversely to disease pathophysiology. INTRODUCTION Eosinophilic disorders, also referred to as eosinophil-associated diseases, consist of a range of infrequent conditions affecting virtually any body compartment and organ.1 The most commonly affected areas include the bone marrow, blood, mucosal sur- faces, and skin, often with immense disease- and treatment-related morbidity, Disclosure Statement: Dr Bochner’s research efforts are supported by grants AI072265, AI097073 and HL107151 from the National Institutes of Health. He has current or recent consul- ting or scientific advisory board arrangements with, or has received honoraria from, Sanofi-A- ventis, Pfizer, Svelte Medical Systems, Biogen Idec, TEVA, and Allakos, Inc. and owns stock in Allakos, Inc. and Glycomimetics, Inc. He receives publication-related royalty payments from Elsevier and UpToDate and is a coinventor on existing and pending Siglec-8-related patents and, thus, may be entitled to a share of future royalties received by Johns Hopkins University on the potential sales of such products.
    [Show full text]
  • The Cytokine Network in Asthma and Chronic Obstructive Pulmonary Disease
    The cytokine network in asthma and chronic obstructive pulmonary disease Peter J. Barnes J Clin Invest. 2008;118(11):3546-3556. https://doi.org/10.1172/JCI36130. Review Series Asthma and chronic obstructive pulmonary disease (COPD) are very common inflammatory diseases of the airways. They both cause airway narrowing and are increasing in incidence throughout the world, imposing enormous burdens on health care. Cytokines play a key role in orchestrating the chronic inflammation and structural changes of the respiratory tract in both asthma and COPD and have become important targets for the development of new therapeutic strategies in these diseases. Find the latest version: https://jci.me/36130/pdf Review series The cytokine network in asthma and chronic obstructive pulmonary disease Peter J. Barnes National Heart & Lung Institute, Imperial College London, London, United Kingdom. Asthma and chronic obstructive pulmonary disease (COPD) are very common inflammatory diseases of the air- ways. They both cause airway narrowing and are increasing in incidence throughout the world, imposing enormous burdens on health care. Cytokines play a key role in orchestrating the chronic inflammation and structural changes of the respiratory tract in both asthma and COPD and have become important targets for the development of new therapeutic strategies in these diseases. Introduction Inflammation in asthma and COPD The most common inflammatory diseases of the airways are Despite the similarity of some clinical features of asthma and asthma and chronic obstructive pulmonary disease (COPD), COPD, there are marked differences in the pattern of inflamma- and the incidence of both is increasing throughout the world. tion in the respiratory tract, with different inflammatory cells, The prevalence of asthma in developed countries is approxi- mediators, consequences, and responses to therapy (1).
    [Show full text]
  • Importance of Cytokines in Murine Allergic Airway Disease and Human Asthma Fred D
    Importance of Cytokines in Murine Allergic Airway Disease and Human Asthma Fred D. Finkelman, Simon P. Hogan, Gurjit K. Khurana Hershey, Marc E. Rothenberg and Marsha Wills-Karp This information is current as of September 29, 2021. J Immunol 2010; 184:1663-1674; ; doi: 10.4049/jimmunol.0902185 http://www.jimmunol.org/content/184/4/1663 Downloaded from References This article cites 257 articles, 63 of which you can access for free at: http://www.jimmunol.org/content/184/4/1663.full#ref-list-1 Why The JI? Submit online. http://www.jimmunol.org/ • Rapid Reviews! 30 days* from submission to initial decision • No Triage! Every submission reviewed by practicing scientists • Fast Publication! 4 weeks from acceptance to publication *average by guest on September 29, 2021 Subscription Information about subscribing to The Journal of Immunology is online at: http://jimmunol.org/subscription Permissions Submit copyright permission requests at: http://www.aai.org/About/Publications/JI/copyright.html Email Alerts Receive free email-alerts when new articles cite this article. Sign up at: http://jimmunol.org/alerts The Journal of Immunology is published twice each month by The American Association of Immunologists, Inc., 1451 Rockville Pike, Suite 650, Rockville, MD 20852 Copyright © 2010 by The American Association of Immunologists, Inc. All rights reserved. Print ISSN: 0022-1767 Online ISSN: 1550-6606. Importance of Cytokines in Murine Allergic Airway Disease and Human Asthma ,†,‡ x { Fred D. Finkelman,*x Simon P. Hogan, Gurjit K. Khurana Hershey, Marc E. Rothenberg, and Marsha Wills-Karp‡ Asthma is a common, disabling inflammatory respira- lymphocytosis and mastocytosis; alternative macrophage ac- tory disease that has increased in frequency and severity tivation; epithelial cell proliferation with goblet cell hyper- in developed nations.
    [Show full text]
  • Asthma in Children
    ISSN: 2573 - 9611 Research article Journal of Pediatrics & Neonatal Biology Asthma in Children Siniša Franjić Independent Researcher *Corresponding author Siniša Franjić, Independent Researcher Submitted: 29 Jan 2021; Accepted: 07 Feb 2021; Published: 12 Feb 2021 Citation : Siniša Franjić (2021) Asthma in Children J Pediatr Neonatal Biol, 6: 01-04 Abstract Asthma is one of the most common chronic diseases of the airways, characterized by allergic inflammation in the air- ways, often as a result of exposure to allergens, cold air, tobacco smoke, exercise, or emotional stress. The most common asthma symptoms in children are: cough, shortness of breath with wheezing, chest pressure and shortness of breath. Asthma is an incurable disease, but its symptoms, which range from mild to life-threatening, can be controlled with medication and lifestyle, thus ensuring a full and normal life for the child. Keywords: Asthma, Disease, Children, Management Introduction Asthma is a disorder affecting conducting airways in which in- Asthma is a condition characterised by airway obstruction due to flammation interacts with structural changes to cause variable air- bronchial smooth muscle constriction and inflammation that is at flow limitation [3]. Conventional treatment of established asthma least partly reversible [1]. Any asthmatic is susceptible to suffering is highly effective in controlling symptoms and improving quality from an exacerbation (‘asthma attack’), which may be caused by of life. With the possible exception of immunotherapy, however, allergic triggers (e.g. pollen, mould), respiratory infection, med- no treatment has been shown to modify long-term outcomes and ications (e.g. NSAIDs or β-blockers) or lack of compliance with no cure has been identified.
    [Show full text]